Analysts Issue Forecasts for Novo Nordisk A/S’s Q1 2019 Earnings (NVO)

Share on StockTwits

Novo Nordisk A/S (NYSE:NVO) – Analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for Novo Nordisk A/S in a research report issued on Thursday, March 14th. Jefferies Financial Group analyst P. Welford anticipates that the company will post earnings per share of $0.62 for the quarter. Jefferies Financial Group currently has a “Hold” rating on the stock. Jefferies Financial Group also issued estimates for Novo Nordisk A/S’s Q2 2019 earnings at $0.62 EPS, Q3 2019 earnings at $0.64 EPS, Q4 2019 earnings at $0.61 EPS, FY2019 earnings at $2.48 EPS, FY2020 earnings at $2.86 EPS, FY2021 earnings at $3.19 EPS and FY2023 earnings at $3.74 EPS.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Friday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.57 by ($0.03). Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. The firm had revenue of $4.55 billion during the quarter, compared to analyst estimates of $4.36 billion.

Several other analysts also recently issued reports on the stock. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 29th. They issued an “outperform” rating for the company. Barclays reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 5th. JPMorgan Chase & Co. raised shares of Novo Nordisk A/S from a “neutral” rating to an “overweight” rating in a research report on Monday, November 19th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, February 1st. They set an “equal weight” rating for the company. Finally, Deutsche Bank reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Monday, December 10th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $52.31.

Shares of NYSE:NVO opened at $50.89 on Friday. Novo Nordisk A/S has a 52-week low of $41.23 and a 52-week high of $51.64. The company has a market capitalization of $123.40 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 2.33 and a beta of 0.59.

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Novo Nordisk A/S by 8.3% in the fourth quarter. Geode Capital Management LLC now owns 39,942 shares of the company’s stock valued at $1,840,000 after buying an additional 3,060 shares during the last quarter. Princeton Global Asset Management LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $55,000. Valley National Advisers Inc. lifted its stake in Novo Nordisk A/S by 1,012.4% in the fourth quarter. Valley National Advisers Inc. now owns 10,245 shares of the company’s stock valued at $472,000 after buying an additional 9,324 shares during the last quarter. Headinvest LLC lifted its stake in Novo Nordisk A/S by 94.4% in the fourth quarter. Headinvest LLC now owns 203,830 shares of the company’s stock valued at $9,390,000 after buying an additional 98,990 shares during the last quarter. Finally, Equitable Trust Co. lifted its stake in Novo Nordisk A/S by 11.6% in the fourth quarter. Equitable Trust Co. now owns 6,359 shares of the company’s stock valued at $293,000 after buying an additional 663 shares during the last quarter. 7.08% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Read More: Market Capitalization – What it Means for Investors

Earnings History and Estimates for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bibox Token Price Tops $0.33 on Top Exchanges
Bibox Token Price Tops $0.33 on Top Exchanges
ITEX Co.  Declares Semi-Annual Dividend of $0.10
ITEX Co. Declares Semi-Annual Dividend of $0.10
Acacia Mining  Stock Rating Reaffirmed by Berenberg Bank
Acacia Mining Stock Rating Reaffirmed by Berenberg Bank
Fraport AG Frankfurt Arprt Svcs Wrldwde  PT Set at €65.00 by Royal Bank of Canada
Fraport AG Frankfurt Arprt Svcs Wrldwde PT Set at €65.00 by Royal Bank of Canada
Crawford Investment Counsel Inc. Sells 11,400 Shares of Mercury General Co.
Crawford Investment Counsel Inc. Sells 11,400 Shares of Mercury General Co.
Comparing THK CO LTD/ADR  and DUFRY AG/ADR
Comparing THK CO LTD/ADR and DUFRY AG/ADR


© 2006-2019 Ticker Report